

March 21, 2017

Nissan Chemical Industries, Ltd.

**Strategic research collaboration to create a novel drug candidate  
with Mitsubishi Tanabe Pharma**

Nissan Chemical Industries, Ltd. (Head Office: Tokyo, Japan; President & CEO: Kojiro Kinoshita; hereinafter called “Nissan Chemical”) announced the conclusion of the strategic research collaboration agreement with Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, Japan; President and Representative Director: Masayuki Mitsuka) to create a novel drug candidate for autoimmune diseases. Both two companies started the research collaboration using compounds discovered by Nissan Chemical.

Both two companies will strive to provide an innovative drug to patients through this collaboration.

**About Nissan Chemical Industries, Ltd.**

Nissan Chemical Industries, Ltd. is now moving forward to develop new products and businesses through utilization of our core technologies as the chemical company with our corporate vision of becoming "a corporate group that contributes to human survival and development". Nissan Chemical entered into the pharmaceutical business in 1982, and launched an external preparation of ketoprofen, a Ca antagonist and a statin agent with a strong LDL cholesterol reduction. We keep trying research and development for innovative medicines by using precise organic synthesis technology, the strategic chemical library and the state-of-the-art evaluation technology for the smile and precious life around the world. For more details, please visit <http://www.nissanchem.co.jp/eng/>